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Hepatic fibrosis is a dynamic process characterized by the net
accumulation of extracellular matrix resulting from chronic liver
injury of any etiology, including viral infection, alcoholic liver disease,
and nonalcoholic steatohepatitis (NASH). Activation of hepatic stellate
cells (HSCs) causes transdifferentiation of quiescent cells into
proliferative, and fibrogenic myofibroblasts which are now well
established as a central driver of fibrosis. Recently, retinoic acid
receptor-related orphan receptor alpha (RORα) has been demonstrated
to have the effects on mitochondrial function in hepatocytes and
M1/M2 polarization in Kupffer cells, thereby attenuates NASH. Here,
I investigated the effect of a potential RORα agonist, ODH 2-12 in
the activation of HSCs and in diet-induced fibrosis mice model. First,
- ii -
activation of RORα by transient overexpression had an anti-fibrogenic
effect in transforming growth factor-beta 1 (TGFβ1) activated human
HSCs. Second, the anti-fibrotic effect of ODH 2-12 was observed in
the mRNA and protein expression of the fibrogenic markers such as
alpha-smooth muscle actin and collagen type 1 alpha 1 in TGFβ1
activated human HSCs. Third, the effect of ODH 2-12 was also
observed in primary mouse HSCs, in that it reduced expression of
the fibrogenic markers. Fourth, a diet-induced fibrosis mice model
was developed by feeding the western diet. Treatment with ODH
2-12 showed reduced collagen deposition level and expression of
fibrogenic markers. Finally, dual-luciferase reporter assays indicated
that ODH 2-12 reduced the TGFβ1-induced reporter gene expression
in the SMAD reporter. In conclusion, RORα and its agonist ODH
2-12 showed a potential anti-fibrotic effect which would provide a
potential anti-fibrotic strategy.
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Liver fibrosis is a wound-healing response that involves an array of
cell types and mediators to enclose the injury (Friedman 2008). It is a
vigorous process designated by the net accumulation of extracellular
matrix (ECM), caused by the chronic liver injury of any kinds
including chronic viral infection, alcoholic liver diseases (ALD), and
NASH, a progressive form of NAFLD (Tsuchida et al, 2017). Nash is
currently arising as the looming threat in public health worldwide;
however drug development in this area of disease is explosive as it
needed to address complex metabolic dysfunction including fibrosis
and the clinical endpoint of cirrhosis (Angulo et al 2015). Moreover,
that unmitigated fibrosis leads to cirrhosis, with consequences of
increased liver-related mortality and development of cancer or in need
for liver transplantation (Wattacheril et al 2018).
There are diverse cell genres which are considered as the sources
of ECM in liver fibrosis. However, among these cells, activated
hepatic stellate cells (HSCs) are now well established as the main
sources of ECM in liver fibrosis (Schuppan et al 2013). In normal
liver, HSCs maintain a non-proliferative, quiescent, vitamin A storing
phenotype but when activated, they transdifferentiate to
myofibroblasts which are proliferative, contractile, inflammatory and
chemotactic followed by enhanced ECM accumulation (Puche et al
2013). The proliferation of activated HSCs mainly follows four
fibrogenic pathways such as TGFβ (transforming growth factor β),
PDGF (platelet-derived growth factor), VEGF (vascular endothelial
growth factor) and CTGF (connective tissue growth factor). Among
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them, TGFβ1 is generally considered the most influential fibrogenic
cytokine (Hellerbrand et al 1999). TGFβ binding and phosphorylation
of the TGFR1 (type I receptor) induces phosphorylation of
downstream SMAD proteins, primarily SMAD3. Upregulation of
SMAD3 during HSC activation promotes transcription of type I and
type III collagen (Friedman 2008).
Retinoic acid receptor-related orphan receptor alpha (RORα) is a
nuclear receptor which is a member of the steroid/thyroid hormone
receptor superfamily. It binds to a specific DNA sequence named
ROR response element (RORE) either as monomer or homodimer in
the regulatory region of target genes (Jetten, 2009). RORα ligands
such as Cholesterol Sulfate, SR1078, and JC1-40, reversibly bind and
increase the transcriptional activity of target genes (Solt et al 2012,
Kim et al 2012). Moreover, RORα is known to have a pivotal role in
liver diseases. In previous study, we demonstrated that RORα 
attenuates NASH by inhibiting lipid accumulation, oxidative stress
and by inducing M1/M2 polarity in liver macrophages (Kim et al
2012, Han et al 2014, Han et al 2017). It also attenuates NASH by
inducing mitochondrial functions (Kim et al 2017). Recently we found
that in HFD fed RORα–LKO (hepatocyte knockout) mice model, the
liver sections showed increased collagen deposition in Sirius red
staining along with increased expression of fibrogenic marker such as
αSMA, TGFβ1, MMP2, Timp1 (Kim et al 2017). These results
indicate that RORα may have an inhibitory effect on liver fibrosis.
However, the role of RORα in liver fibrosis as well as in HSCs has
not been investigated to date.
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Figure 1. Cellular architecture in liver fibrosis
In liver fibrosis the cellular architecture of liver changes. Especially
HSCs get activated and undergo drastic phenotypical changes. In
normal liver, HSCs are non-proliferative vitamin A-storing cells.
Upon liver injury, the cells start to multiply and lose their vitamin
A-storing capacity. (Adopted from Puche et al 2013)
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Figure 2. Phenotypical changes in HSCs activation
Liver injury initiates the activation of HSCs and cell perpetuation
begins which are characterized by specific phenotypical changes
including proliferation, contractility, fibrogenesis, and chemotaxis. The
resolution of this phenomenon would be either the reversion or
apoptosis of the cells. (Adopted from Tsuchida et al 2017).
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Figure 3. Physiological function and role of RORα in liver
diseases
RORα is a member of steroid/thyroid superfamily of RORs. It binds
to a specific DNA sequences called RORE and activate through ligand
binding to regulate gene expression. RORs plays critical roles in
many physiological processes such as development, circadian rhythm,
metabolism, stress, and hypoxia. RORα is well known to play a
major role in liver diseases including protection from NAFLD and
NASH. (Adopted from Jetten et al 2009, Kim et al 2012, Han et al
2014, Han et al 2017, Kim et al 2017))
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Ⅱ. PURPOSE OF THE STUDY
Liver fibrosis and liver cirrhosis are the major causes of morbidity
and mortality in chronic liver diseases but the prevention and reversal
of this condition have become a major endpoint in clinical trials in
liver-specific drugs. Especially in fibrosis which is induced by
advanced alcoholic or nonalcoholic steatohepatitis (NASH). As it is
now evident that untreated NASH may develop into fibrosis and
further to cirrhosis and hepatocellular carcinoma (HCC). Although
liver fibrosis is reversible but proper drug to treat this condition is
not developed yet. In our previous study, we found that RORα has a
protective effect in NAFLD and NASH. We have found the effect of
RORα in hepatocyte and Kupffer cells which gave us a clear idea of
the role of RORα in NASH conditions. However, we also found that
the pro-fibrotic factors were elevated in the liver of the RORα-LKO
mice. Which took our interest to find out the effect of RORα in liver
fibrosis as well as in the HSCs. There were no significant studies on
the effect of RORα or its agonist in the activation of HSCs.
Therefore, in this study, I aimed to identify the effect of RORα and
its potential agonist ODH 2-12 in the activated HSCs as well as in
the diet-induced liver fibrosis mice model. To investigate this I used
RORα overexpression and SMAD reporter assay approach in hHSC
cell line. In addition, I also evaluated the effect of ODH 2-12 in
hHSC and primary HSCs. To further determine the effect of ODH
2-12, I developed a diet-induced liver fibrosis mouse model by
feeding western diet. Thus I assessed the effect of ODH 2-12.
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Ⅲ. MATERIALS AND METHODS
1. Cell culture and cell treatment
The Lx-2 cell line (an immortalized human HSCs line) was kindly
provided by Professor Kim Sang Geon (College of Pharmacy, Seoul
National University). The cells were cultured Dulbecco’s modified
Eagle’s medium with 10% FBS, 1% penicillin/streptomycin. The cells
were activated with recombinant human TGF-β1 from Peprotech
(Rocky Hill, NJ 08553 USA) which was added to the supernatant at
5.0 ng/ml for 18 h. The Primary HSCs were isolated from 8-9
week-old, male C57/BL6J mouse liver. Under anesthesia with Zoletil
& Rampoon, livers were perfused with Hank’s buffered salt solution
followed by continuous perfusion with a 0.1% (wt/vol) collagenase
(Sigma, Type IV). The separation of stellate cells from
non-parenchymal supernatant was followed by forming concentration
gradient of 52/50/30% percoll (GE Healthcare, Waukesha, WI) and
centrifuging at 2200 rpm for 15 minutes (Vrochides D et al 1996).
The layer containing stellate cells was plated with Dulbecco’s
modified Eagle’s medium with 10% FBS, 1% penicillin/streptomycin.
After 24 h the cells were rinsed in the PBS and maintained in the
similar medium at 37℃ in a humidified atmosphere with 5% CO2.
2. Western diet-induced mice model
The diet-induced liver fibrosis mice were developed by feeding
western diet (Research diet #D12079B) to 7 week-old, male C57/BL6J
mice for 21 weeks. For control mice, low-fat diet (D12450J) with
similar time-span was also fed. ODH 2-12 treatment was started
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from 16 weeks of western diet feeding by oral gavage with the dose
of 10 mg/kg body weight for 5 weeks once a day. After 21 weeks
the mice were sacrificed. The blood serum and liver samples were
collected for further assay. For histological examination, sections of
liver tissue were embedded in parraffin and stained with hematoxin
and eosin (H&E) and Sirius red (Hsservice, 145, Geumnanghwa-ro,
Ganseo-gu, Seoul, Korea).
3. Reporter gene assay
Chang liver cells and Lx-2 cells were seeded in a 24 well plate with
a density of 2.5×104 per well. After 24 h the cells were washed with
1X PBS and changed to a new cell media. In Chang Cells, the cells
were transfected using DNA mixture of expression vectors (RORα,
RORβ, RORγ, PPARα, PPARδ, PPARγ, LXRα) luciferase reporter
promoter (Gal4-tk-Luc), and β-galactosidase vector using polyfect
transfection reagent (QIAGEN). Compound treatment was done for
another 18 h. In Lx-2 cells, expression vectors (myc-EV and
myc-RORα) were transfected with SMAD reporter and β
-galactosidase vector using polyfect transfection reagent. ODH 2-12,
OCA, and TGFβ1 were treated together for another 18 h. To harvest
cell lysate, 200 μl of luciferase cell culture lysis 5X reagent (E1531;
Promega) was used. The luciferase reporter promoter activity was
normalized by β-galactosidase.
4. Western blot assay
Cells were washed with cold 1x PBS and harvested with a RIPA
lysis buffer (25 mM Tris-HCl, 150 mM NaCl, 0.1% sodium dodecyl
sulfate, 1% Triton X-100, 1% deoxycholate, 5 mM EDTA) supplement
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with a protease inhibitor cocktail (11.836.153.001, Roche, Switzerland)
and a phosphatase inhibitor (4906845001, Roche, Switzerland) by using
cell scraper. After 30 minutes of incubation on ice, lysates were
centrifuged at 13,000 rpm for 15 minutes, 4℃. supernatant was
separated and quantified through the BCA Protein Assay Kit (23225,
Pierce, USA). Protein samples were loaded in 7% gel. After
SDS-polyacrylamide gel electrophoresis, proteins were transferred
onto a 0.45 μm polyvinylidene difluoride membrane by semi-dry
transfer method. 1 w/w% non-fat dry milk in PBS with 0.1%
Tween-20 (PBS-T) was used for blocking membrane for 1 hour
under room temperature. After blocking, membranes were incubated
in primary antibodies in 1 w/w% non-fat dry milk in PBS-T
overnight in 4℃. Membranes were washed 3-times with PBS-T and
incubated secondary antibodies for 1 h under room temperature.
Amersham Prime ECL solution (RPN2232, GE healthcare, USA) was
used for detection after washing 3-times with PBS-T to remove
antibodies. Antibodies used in western blottings are anti-αSMA
(ab7817, 1:200 dilution), Anti-COL1A1 (sc-293182, 1:2000 dilution),
anti-COL1A2 (sc-8787, 1:2000 dilution), anti-RORα (sc-6062, 1:2000
dilution), anti-HSP60 (ab45134, 1:20,000 dilution).
5. Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA isolation was done by EASY-BLUETM Total RNA
Extraction Kit (Intron Biotechnology, Korea) according to the
manufacturer's protocol (Lx-2 cells). For primary HSCs, RNA was
extracted using the RNeasy Micro Kit (QIAGEN 74004). Extracted
total RNA was reverse-transcripted to synthesize cDNA using
M-MLV reverse transcriptase (28025-013, Invitrogen). qRT-PCR was
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performed using SYBR Green PCR master mix (4367659, Applied
Biosystems). The resulting ΔCt values were normalized with 18s
rRNA.
6. Statistical analyses
All data were statistically analyzed by using GraphPad Prism 5
(GraphPad Software, USA). Statistical analyses were performed using
unpaired ‘t’ test, non-parametric Mann-Whitney ‘U’ test and one-way
Anova test for comparisons of data. P＜0.05 denotes statistical
significance.
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Table 1. Primer sequences used for quantitative RT-PCR




5'-CTT CAG GGG CAA CAC GAA-3'




5'-AAC ATG ACC AAA AAC CAA AAG TG-3'




5'-GGC AGT GGT TGA GCC GTG GA-3'





5'-GTT CCG ACC ATA AAC GA-3'




5'-TCG TTA CCT CCA AAG GCT GCT C-3'




5'-GAA ACC CGA GGT ATG CTT GA-3'




5'-AGC CAA CCG TGC TTC TCA G-3'




5'-AAG GCT GCA AGA TGG ATG CT-3'





5'-GTA ACC CGT TGA ACC CCA TT-3'
5'-CCA TCC AAT CGG TAG TAG GG-3'
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Ⅳ. RESULTS
1. ODH 2-12 is a potential RORα agonist
To find out a proper agonist of RORα to enhance its possible
anti-fibrotic effect, I used ODH 2-12 which is structurally modified
derivative of JC 1-40. In our previous study, we mentioned that JC
1-40 is a synthetic ligand of RORα and it has an inhibitory effect in
lipid accumulation, oxidative stress thereby attenuates NASH (Kim et
al 2012). To identify ODH 2-12 as a potential ligand of RORα, I
performed the reporter gene assay in Chang cells with nuclear
receptors which play important roles in the liver. The transcriptional
activity of ODH 2-12 was higher towards RORα nuclear receptor in
comparison with other nuclear receptors such as RORβ, RORγ, PPAR
α, PPARδ, PPARγ, LXRα. From this result, I concluded that ODH
2-12 is a potential agonist of RORα.
2. RORα prevents the TGFβ1-induced fibrogenic activation of
HSCs
To investigate whether RORα regulate liver fibrosis, RORα 
overexpression study was done in Lx-2 cells. RORα was transiently
transfected for 24 h and treated with TGFβ1 (5 ng/ml) for another 18
h. After that, expression levels of pro-fibrotic markers were detected
by western blotting and qRT-PCR. Overexpression of RORα reduced
the protein expression of pro-fibrotic marker α-SMA, COL1A1, and
COL1A2. Similarly, the overexpression of RORα reduced the mRNA
expression of pro-fibrotic marker α-SMA and COL1A1. Hence, these
results indicate that RORα prevents the TGFβ1 induced fibrogenic
activation of HSCs.
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3. ODH 2-12 inhibits the TGFβ1-induced fibrogenic activation
of HSCs.
To asses the effect of ODH 2-12 in HSCs, I treated this compound
in Lx-2 cells. ODH 2-12 with 5, 10, 20, 30 μM doses were treated
for 18 h along with TGFβ1 (5 ng/ml). Protein assay and mRNA
assay were conducted to find the effect of ODH 2-12. It reduced the
protein expression of fibrogenic marker α-SMA and COL 1A1 in
comparison with TGFβ1. It also reduced the mRNA expression of
similar fibrogenic markers along with the mRNA expression of TGFβ
1. Hence, this observation indicates that ODH 2-12 inhibits the
activation of HSCs.
4. RORα and ODH 2-12 suppresses the transcriptional activity
of the SMAD reporter
To determine how RORα and ODH2-12 inhibiting the TGFβ1-induced
activation of HSCs I conducted reporter gene assay on the SMAD
reporter in Lx-2 cells. First, I examined the effect of RORα in the
SMAD reporter to find out its effect on the SMAD reporter which
was stimulated by TGFβ1 (5 ng/ml). RORα dose-dependently
downregulated the transcriptional activity of the SMAD reporter
Second, I carried out a similar assay with ODH 2-12 and Obeticholic
acid (OCA) without RORα. Both compounds downregulated the
transcriptional activity of the SMAD reporter. Finally, to explore the
effect of ODH 2-12 with RORα, I performed the reporter assay in the
SMAD reporter and found out that in the presence of ODH 2-12,
RORα also suppresses the transcriptional activity.
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5. ODH 2-12 reduces the expression of fibrogenic markers in
primary HSCs.
In addition, to investigate the effect of ODH 2-12 in primary HSCs I
treated this compound in isolated primary HSCs. At first, I confirmed
the activation of cultured primary HSCs by their morphological
changes (microscopical pictures) for 6 days and extracted RNAs from
1st, 3rd, 5th, and 6th day and performed qRT-PCR assay. Notably, it is
known that primary HSCs starts to activate spontaneously after 24 h
of cell culture. mRNA expression studies from 1st, 3rd, 5th, and 6th
day showed steady upregulation of pro-fibrogenic marker α-SMA,
COL1A1 and COL3A1 expression and further confirmed the procedure.
Next, I treated the cultured primary HSCs with ODH 2-12 from day
1 to day 6 and conducted qRT-PCR assay. Treatment with ODH
2-12 decreased the mRNA expression of similar fibrogenic marker α
-SMA, COL1A1 and COL3A1. This observation further indicates that
ODH 2-12 also inhibits the activation of primary HSCs.
6. ODH 2-12 treatment prevents diet induced liver fibrosis in
vivo
To further asses the effect of ODH 2-12 in vivo I developed
diet-induced liver fibrosis mice model. I fed the mice western diet for
21 weeks. Drug treatment has been done from 16 weeks to 21 weeks
and after that, the mice were sacrificed and blood serum & liver
tissues were collected and further studies are performed. ODH 2-12
treated WD mice shown decreased liver weight, ALT and AST level
in comparison with WD fed mice. The H&E staining and Sirius red
staining also showed decreased lipid, and collagen deposition in WD
fed ODH 2-12 treated mice. The protein expression of fibrogenic
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marker α-SMA and COL1A1 were decreased in ODH 2-12 treated
mice in comparison with WD fed mice. Consistently, mRNA
expression of pro-fibrogenic marker α-SMA, COL1A1, and COL1A2
also decreased in ODH 2-12 treated mice.
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Figure 4. ODH 2-12 is a potential RORα agonist
(A) Chemical structure of JC 1-40 and its structurally modified derivative
ODH 2-12.
(B) Chang cells were transfected by pM-hRORα, pM-hRORβ, pM-hRORγ,
pM-mPPARα, pM-mPPARδ, pM-mPPARγ, and pM-hLXRα with the
Gal4-tk-Luc and β-galactosidase for 24 h. After transfection, cells were
treated with ODH 2-12 (20 μM), and respective agonist of each vector for
18 h. The statistical analysis was performed by unpaired ‘t’ test, (n=3,
*p<0.05, and ***, ###p<0.001).
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Figure 5. RORα prevents the TGFβ1-induced fibrogenic
activation in hHSCs
Lx-2 cells were seeded into 60 mm plates at a density of 3x105 cells
per well and cells were transiently transfected with myc-EV and
myc-RORα (1, 3, 6 μg for protein and 6 μg for mRNA study) for 24
h and then replaced with new culture medium which then treated
with or without 5.0 ng/ml TGFβ1 for another 18 h. (A) Western
blotting was performed to analyze the protein levels and (B)
real-time qPCR was performed to analyze the mRNA levels of
fibrogenic marker α-SMA, COL1A1 and TGFβ1. The statistical
analysis was performed by following non-parametric Mann-Whitney
‘U’ test, (*p<0.05, ***, ###p< 0.001).
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Figure 6. Treatment of ODH 2-12 inhibits the TGFβ1-induced
fibrogenic activation in hHSCs
Lx-2 cells were seeded into 60 mm plates at a density of 3×105 cells
per well, and cells were treated with ODH 2-12 (5, 10, 20, 30 μM)
and with or without 5.0 ng/mL TGFβ1 for 18 h. (A) Western blotting
was performed to analyze the protein levels and (B) real-time qPCR
was performed to analyze the mRNA levels of α-SMA, COL1A1, and
TGFβ1. The statistical analysis was performed by following one-way
Anova test, (n=4, *p<0.05, ***p<0.001).
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Figure 7. TGFβ1/SMAD signalling in fibrosis
The proliferation of activated HSCs mainly follows four fibrogenic
pathways such as TGFβ1 (transforming growth factor β1), PDGF
(platelet-derived growth factor), VEGF (vascular endothelial growth
factor) and CTGF (connective tissue growth factor). Among them,
TGFβ1 is considered the most potent fibrogenic cytokine. TGFβ1
binding and phosphorylation of the type I receptor induces
phosphorylation of downstream SMAD proteins, predominantly
SMAD3. The SMAD3 component directly binds to gene promoters to
induce transcription of pro-fibrotic molecules, including α-SMA,
collagen I and collagen III which induce myofibroblast activation and
matrix deposition. (Adopted from Meng et al 2016).
- 20 -
Figure 8. RORα & ODH 2-12 suppresses the transcriptional
activity of SMAD reporter
(A) Lx-2 cells were transiently transfected by SMAD cignal reporter,
β-galactosidase, myc-EV, and myc-RORα (20, 50, 100 ng) for 24 h
and then replaced with new culture medium. After that treated with
or without 5.0 ng/ml TGFβ1 for another 18 h.
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(B) The Lx-2 cells were treated with SMAD cignal reporter,
β-galactosidase for 24 h. ODH 2-12 and OCA (obeticholic acid) was
treated with the dose 10 and 20 μM for 18 h with TGFβ1 (5.0 ng/ml)
(C) The Lx-2 cells were transfected with SMAD cignal reporter,
myc-RORα (20 ng) and β-galactosidase. Then treated with ODH
2-12 (10, 20 μM) for 18 h along with TGFβ1 (5.0 ng/ml).
The luciferase reporter promoter activity was normalized by
β-galactosidase. The results are presented by following one-way
Anova test, (n=3, *p<0.05, ***p<0.001).
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Figure 9. Isolation and activation of primary HSCs
Primary HSCs were isolated and cultured for 6 days consecutively in
12 well plate. (A) The morphological changes and activation of cells
are showed through cell microscopic pictures (X400). (B) Real-time
qPCR was performed to analyze the mRNA levels of α-SMA,
COL1A1, and COL3A1. The statistical analysis is performed by
following one-way Anova test, (n=3, *p<0.05, ***p<0.001).
- 23 -
Figure 10. ODH 2-12 treatment reduces the expression of
fibrogenic markers expression in primary HSCs
After isolation of primary hHSCs, ODH 2-12 (1, 2 μM) were treated
for 6 days consecutively. Real-time qPCR was performed to analyze
the mRNA levels of α-SMA, COL1A1, and COL3A1. The statistical
analysis is performed by following one-way Anova test, (n=3, *p<
0.05).
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Figure 11. ODH 2-12 treatment in vivo reduces liver weight,
AST, and ALT
(A) WD and LFD diet feeding started with 7 weeks old C57BL/6J
mice and continued until 21 weeks. ODH 2-12 was treated from 16
weeks to 21 weeks by oral gavage (QD) 10 mg/kg body weight.
After 21 weeks, animals were sacrificed. (B) Comparison of liver
weight among LFD + VEH (n=11), LFD + ODH 2-12 (n=8). WD +
VEH (n=14), and WD + ODH 2-12 (n=12) fed mice. (C) The AST
and ALT levels were measured from blood serum with the same
numbers of mice. The statistical analysis was performed following
non-parametric Mann-Whitney ‘U’ test, (*p<0.05, ***, ###p<0.001).
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Figure 12. ODH 2-12 treatment in vivo reduces the lipid and
collagen deposition
Liver tissue sections were obtained from mice described in figure 11.
(A) Representative H&E staining picture of the liver sections from
LFD fed vehicle (VEH) and ODH 2-12, and WD fed vehicle (VEH)
and ODH 2-12 mice.
(B) Representative Sirius red staining picture of the liver sections
from LFD fed vehicle (VEH) and ODH 2-12, and WD fed vehicle
(VEH) and ODH 2-12 mice.
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Figure 13. ODH 2-12 treatment in vivo reduces the protein and
mRNA expression
WD diet-induced mice liver tissues (described in figure 11) were
further analyzed to find out the protein and mRNA expression of
fibrogenic markers. (A) Western blotting was performed to analyze
the protien levels (n=4) and (B) real time qRT-PCR was performed
to analyze the mRNA levels of fibrogenic markers α-SMA, COL1A1
and COL1A2. The statistical analysis was performed following
non-parametric Mann-Whitney ‘U’ test, (LFD + VEH (n=9), WD +
VEH (n=10) & WD + ODH 2-12 (n=11), *p<0.05), ***p<0.001).
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V. DISCUSSION
It has been well established now that HSCs plays major roles in liver
fibrosis. Activation of these cells is the main driver for the
accumulation of fibroblasts and extracellular matrix which results in
liver fibrosis (Friedman 2006). Upon liver injury, activated stellate
cells undergo a perpetuation phase which includes proliferation,
contractility of myofibroblasts which produce TGFβ1 (Tsuchida et al
2017). On the other hand, TGFβ1 stimulates the further uncontrolled
activation of cells to multiply and to increase the amount of ECM per
cells (Puche et al 2013). Therefore to prevent the fibrogenic activation
of these cells became a critical point in the treatment of liver fibrosis.
In this study, I aimed to inhibit the fibrogenic activation of HSCs in
order to prevent the overall liver fibrosis.
Although, there are several studies about inhibiting the activation of
stellate cells or suppression of TGFβ1/SMAD signaling by using
nuclear receptors including PPARγ (Hazra et al 2004), NR4A1 (Zerr
et al 2014), NRF2 (Prestigiacomo et al 2018). However, in this study,
for the first time, I demonstrated that RORα has an inhibitory effect
in HSCs fibrogenic activation as well as in liver fibrosis. RORα is a
multifunctional nuclear receptor which plays a critical role in many
physiological processes. Notably, it has a crucial role in liver diseases.
We previously demonstrated that it plays a protective role in NAFLD
and NASH. Recently, we also showed that in HFD fed RORα-LKO
(hepatocytes specific) mice model, there were considerably more
collagen deposition and upregulated α-SMA expression (Kim et al
2017). Following these findings, we came with the hypothesis that
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RORα has an inhibitory effect in the liver fibrosis. To prove this
hypothesis, I sought out the effect of RORα in the fibrogenic
activation of HSCs. However, there were no significant previous
studies on the effect of RORα in HSCs.
In this study, I activated HSCs (Lx-2 cells) by TGFβ1 and
performed the RORα overexpression study. The protein and mRNA
expression study revealed that overexpression of RORα reduces the
expression of key pro-fibrotic markers α-SMA and COL1A1
significantly. However, RORα is a ligand binding NR which by
binding to its agonist promote the transcriptional expression of the
target gene, therefore proper agonist is needed which can activate the
RORα. In this study, I used the ODH 2-12 compound with the hope
that it might be an appropriate agonist of RORα in order to boost
the anti-fibrotic effect of RORα. To prove ODH 2-12 is an agonist of
RORα I carried out reporter gene assay to find out the selective
transcriptional activity of ODH 2-12 in different liver important NRs.
The reporter gene assay results showed that ODH 2-12 has higher
transcriptional activity towards RORα comparing other RORs (RORβ 
and RORγ) and other important NRs such as PPARs and LXRα.
Despite this study, further ligand binding studies are needed to
confirm ODH 2-12 as a selective agonist of RORα.
In resemblance to RORα, treatment of ODH 2-12 in Lx-2 cells has
shown similar inhibitory effect in both protein and mRNA expression
of the fibrogenic marker which was induced by TGFβ1. Additionally,
to find the mechanism of how RORα and ODH 2-12 expressing
anti-fibrotic effect I conducted SMAD reporter assay which expresses
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the transcriptional activity of SMAD reporter. RORα and ODH 2-12
both suppress the transcriptional activity of the SMAD reporter.
However, this study does not define the exact mechanism of how
RORα and ODH 2-12 are suppressing the SMAD. Nevertheless, this
finding is indicative of the role of RORα in the TGFβ1 and SMAD
signaling. Additionally, detailed mechanism studies are needed to find
out the exact mechanism of RORα mediated suppression of SMAD
pathway. Furthermore, to find out the effect of ODH 2-12 in vivo, I
developed a fibrosis mice model which is induced by WD. Although
there is another diet system, named as MCD (Methionine and
choline-deficient) diet, which is also known to induce fibrosis in the
liver. However, I choose WD because it contains high fat, cholesterol,
and a combination of high-fructose corn syrup, sucrose, fructose, or
glucose which eventually leads to metabolic syndrome along with
NAFLD with fibrosis, making this diet most suitable for my research
goal. On the other hand, the MCD diet is incapable of inducing
metabolic syndrome and also does not induces NAFLD and fibrosis
consistently. Therefore, the clinical significance of the MCD diet is
questionable (Stephenson et al 2018).
Treatment of ODH 2-12 in vivo has shown significant anti-fibrotic
effect in the diet-induced liver fibrosis mice model. It reduced the
liver weight and AST and ALT levels which indicates that it
improved the NAFLD condition in vivo. Moreover, in the histological
liver tissue examination, marked decreased of collagen deposition in
Sirius red staining indicates attenuation of fibrosis. Finally, the
decreased expression of fibrogenic markers in both protein and mRNA
assay has provided further evidence of the anti-fibrotic effect of ODH
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2-12. Although, in animal model, I only evaluated the effect of ODH
2-12 in liver tissues, not specifically in the HSCs. Therefore, further
studies can be conducted either on the HSCs of this diet-induced
mice model or in mice, where RORα is conditionally knockout from
other liver cells except HSCs.
In conclusion, I have demonstrated that ODH 2-12 could be a
promising anti-fibrotic agent although further studies are needed to
find out the full potential of this compound in vivo and in vitro. In
addition, it has the potential to be a proper agonist of RORα which
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간 섬유화는 바이러스 감염, 알콜성 간질환 및 비알콜 성 지방 간염 (NASH)을
비롯한 모든 원인의 만성 간 손상으로 인한 세포 외 기질의 순 축적을 특징으
로하는 동적 과정이다. 간 성상 세포의 활성화 (HSCs)는 비활성 세포를
섬유증의 주 요인인 증식성의 섬유 myofibroblasts로 전이 분화시킨다.
최근 retinoic acid receptor related orphan receptor α (RORα)은 간세포
에서의 미토콘드리아 기능 및 쿠퍼 세포에서의 M1 / ​M2 분극화에 영향
을 미침으로써 NASH를 약화시키는 것으로 나타났다. 여기에서, 우리는
활성화 된 HSCs 및 식이 유도 된 섬유증 쥐 모델에서 잠재 RORα 작용
제, ODH 2-12의 효과를 조사하였다. 첫째, 우리는 RORα 과발현이 형질
전환 transforming growth factor beta 1 (TGFβ1)로 활성화 된 인간 HSCs
에서 항 섬유화 효과가 있고 ODH 2-12가 RORα의 전사 활성을 유도한
다는 것을 관찰했다. 둘째, 우리는 ODH 2-12의 항섬유화 효과를 관찰하
고, TGFβ1-활성화 인간 HSCs에서 Alpha Smooth Muscle Actin 및
Collagen type 1 Alpha 1과 같은 섬유성 마커의 mRNA 및 단백질 발현
을 감소시키는 것으로 나타났다. 셋째, 우리는 일차 마우스 HSCs에서
ODH 2-12의 효과를 조사하였으며 섬유화 마커에 대해 유사한 감소 효
과를 보였다. 다음으로, 우리는 식이요법으로 유도된 섬유증 마우스 모델
을 서양 식단에 먹이로 개발했습니다. ODH 2-12 처리는 간 조직학에서
감소된 콜라겐 침착을 보여주었고 fibrogenic 마커의 mRNA와 단백질
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발현도 감소시켰다. 마지막으로, 이중 루시퍼 라제 리포터 분석은 ODH
2-12가 SMAD 신호 전달 경로에서 TGFβ1-유도 리포터 유전자 발현을
감소시킨다는 것을 나타내었다. 결론적으로, ODH 2-12는 잠재적인 항
섬유화 효과를 나타내므로 잠재적 항섬유화 제제의 후보 물질이 될 수
있다.
주요어: RORα agonist, Hepatic stellate cells, Diet-induced
fibrosis
학 번 : 2017-24003
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